The estimated Net Worth of Bruce J Jr. Mc Creedy is at least $13.9 Тысяча dollars as of 11 February 2020. Bruce Creedy owns over 8,700 units of Salarius Pharmaceuticals stock worth over $13,920 and over the last 5 years he sold SLRX stock worth over $0. In addition, he makes $0 as Interim Chief Scientific Officer and Director at Salarius Pharmaceuticals.
Bruce has made over 1 trades of the Salarius Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 8,700 units of SLRX stock worth $10,005 on 11 February 2020.
The largest trade he's ever made was buying 8,700 units of Salarius Pharmaceuticals stock on 11 February 2020 worth over $10,005. On average, Bruce trades about 1,088 units every 0 days since 2019. As of 11 February 2020 he still owns at least 8,700 units of Salarius Pharmaceuticals stock.
You can see the complete history of Bruce Creedy stock trades at the bottom of the page.
Dr. Bruce J. McCreedy Jr., Ph.D. serves as Interim Chief Scientific Officer and Director of the Company. Dr. McCreedy has served as a member of Salarius’ board of directors since July 2019 and currently serves as Salarius' interim Chief Science Officer. Since September 2015, Dr. McCreedy has served as the senior vice president of cell therapy at Precision Biosciences, Inc., a biotechnology company. Prior to his position at Precision Biosciences, Dr. McCreedy served as the executive vice president of research and development and chief development officer of Neximmune, Inc., a biotechnology company, from April 2011 to August 2015, and the managing partner of PharmaNav, LLC, a biotechnology company, from 2008 to 2011. From 2006 to 2008, Dr. McCreedy served as vice president of strategic and clinical development at Metabolon, Inc., a metabolomics company and from 2002 to 2006 served as the president, chief executive officer and a director for Fulcrum Pharma Developments, Inc., a drug development company (acquired by Icon plc). Prior to 2002, Dr. McCreedy has also served in various roles at Triangle Pharmaceuticals, Inc., a pharmaceutical company (acquired by Gilead Sciences, Inc.), Therapyedge, Inc., a healthcare and information services company (acquired by Advanced Biological Laboratories S.A.), Laboratory Corporation of America Holdings, a clinical laboratory network, and Roche Biomedical Laboratories, Inc., a drug development company. Dr. McCreedy earned a B.S. in Medical Microbiology from Wake Forest University and a Ph.D. in Microbiology and Immunology from Wake Forest University School of Medicine.
Bruce McCreedy is 60, he's been the Interim Chief Scientific Officer and Director of Salarius Pharmaceuticals since 2019. There are 4 older and 4 younger executives at Salarius Pharmaceuticals. The oldest executive at Salarius Pharmaceuticals, Inc. is Arnold Hanish, 72, who is the Independent Director.
Bruce's mailing address filed with the SEC is C/O SALARIUS PHARMACEUTICALS, INC., 2450 HOLCOMBE BLVD., SUITE JX, HOUSTON, TX, 77021.
Over the last 5 years, insiders at Salarius Pharmaceuticals have traded over $0 worth of Salarius Pharmaceuticals stock and bought 487,662 units worth $209,636 . The most active insiders traders include David J. Arthur, Mark J Rosenblum и Arnold C Hanish. On average, Salarius Pharmaceuticals executives and independent directors trade stock every 40 days with the average trade being worth of $33,925. The most recent stock trade was executed by Tess Burleson on 7 June 2022, trading 27,700 units of SLRX stock currently worth $4,986.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and potential biomarkers for Seclidemstat (SP-2577). Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
Salarius Pharmaceuticals executives and other stock owners filed with the SEC include: